IMV News and Press, IMV Inc. From 03/16/23

2023-03-16 11:02:08 ET IMV Inc. (IMV) Q4 2022 Earnings Conference Call March 16, 2023 08:00 ET Company Participants Andrew Hall - Chief Executive Officer Brittany Davison - Chief Accounting Officer Jeremy Graff - Chief Scientific Officer Conference Call Par...

2023-03-16 07:23:20 ET IMV press release ( NASDAQ: IMV ): FY GAAP EPS of -$4.55 beats by $0.69 . Revenue of $0.33M (+73.7% Y/Y) misses by $0.01M . For further details see: IMV GAAP EPS of -$4.55 beats by $0.69, revenue of $0.33M misses by $0.01M

Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platform Observed multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment of stage one in the VITALIZE study in Q2 2023...

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to...

Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today announced that it has filed patent infringement lawsuits against several companies of the Xiaomi-Group in Germany, France and India. Immersion filed complaints against Xiaomi-Group companies ...

GAAP Net Income of $19.7 million or $0.60 per diluted share Non-GAAP Net Income of $14.8 million or $0.45 per diluted share Declares Quarterly Dividend Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today reported fina...

Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials IMV Inc. (Nasdaq...

Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today announced it has signed a license agreement with Vishay Intertechnology, Inc. (NYSE: VSH)(“Vishay”) to bundle Immersion haptic patent licenses for purchasers of Vishay’s ...

Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position with the...

Announces Special Dividend and $50 Million Stock Repurchase Program Focus on driving multi-year step function increase in valuation Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today reported management changes, a special ca...